People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 pounds. That's according to the study funded by Lilly, which was published this week in NEJM.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
